3c62910d-9304-40bd-a286-d3c1fa199d89
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 66.1656399726215
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.360
- PROTEIN_SECRETION+0.350
- OXIDATIVE_PHOSPHORYLATION+0.250
- FATTY_ACID_METABOLISM+0.180
- DNA_REPAIR+0.120
- SPERMATOGENESIS+0.120
- HEME_METABOLISM+0.110
- PANCREAS_BETA_CELLS+0.100
- ANDROGEN_RESPONSE+0.040
- MYC_TARGETS_V2+0.040
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.490
- ANGIOGENESIS-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- MYOGENESIS-0.320
- APICAL_JUNCTION-0.310
- WNT_BETA_CATENIN_SIGNALING-0.310
- COAGULATION-0.290
- MITOTIC_SPINDLE-0.280
- IL6_JAK_STAT3_SIGNALING-0.220
- INTERFERON_GAMMA_RESPONSE-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1350220 | GTEX | — | 0.807 |
| 2 | 3ba89ed5-e704-40d1-bb04-5a0ba48e446d | — | — | 0.802 |
| 3 | e74cd5d1-66e1-4008-8b9a-170392f7cbb8 | — | — | 0.795 |
| 4 | BS_6T4JGBGY | Embryonal tumors | — | 0.783 |
| 5 | df4e44f9-ee22-43d3-911e-fd4bd826ec0c | — | — | 0.780 |
| 6 | SRR12696775 | — | — | 0.779 |
| 7 | s0095168 | — | — | 0.771 |
| 8 | SRR33346955 | — | — | 0.764 |
| 9 | 20140146.LumB | — | B | 0.755 |
| 10 | C3L-00140 | — | cohortA2 | 0.755 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.040 | Idelalisib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.030 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.010 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.010 | Inavolisib | — uncovered |